Schedule One update - Gelion PLC

COMPANY NAME:

Gelion PLC ("Gelion" or the "Company")

COMPANY REGISTERED OFFICE ADDRESS AND IF DIFFERENT, COMPANY TRADING ADDRESS (INCLUDING POSTCODES) :

Registered office:

Gelion UK Ltd

3rd Floor, 141 145 Curtain Road

London

EC2A 3BX

Trading address:

Cicada Innovations

National Innovation Centre

Cornwallis Street

Eveleigh

NSW 2015

Australia

COUNTRY OF INCORPORATION:

United Kingdom

 www.gelion.com

COMPANY BUSINESS (INCLUDING MAIN COUNTRY OF OPERATION) OR, IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS INVESTING POLICY).  IF THE ADMISSION IS SOUGHT AS A RESULT OF A REVERSE TAKE-OVER UNDER RULE 14, THIS SHOULD BE STATED:

Gelion plc is a UK-Australian energy-storage innovator founded in 2015 by Professor Thomas Maschmeyer as a spin-out from the University of Sydney, Australia's first university.

Operating primarily out of Australia, the Company was established to commercialise Professor Maschmeyer's discovery of a battery cell that controls the electrochemistry of zinc-bromide reactions without the need for a flowing electrolyte. This has allowed Gelion to produce its "Endure" battery, which is ideally suited for off-grid and grid connected storage of renewable energy across a range of industries. The Endure battery is protected by patents and patent applications in all core jurisdictions in which Gelion seeks to operate.

The Endure zinc-bromide battery is designed to provide a safe, cost-effective, long-life and recyclable alternative to lithium-ion and lead-acid (PbA) battery technologies for stationary storage of renewable energy. Gelion's battery can be manufactured using brownfield lead-acid battery production facilities, keeping capital costs very low when compared to other technologies for stationary energy.

The battery technology is highly resistant to fire, even under extreme, deliberate fault scenarios, and can be completely discharged with no loss of function, or damage to the battery. Unlike lithium-ion and PbA batteries the Endure batteries are highly tolerant to temperature extremes, making them well suited for operation without need for expensive air-conditioning systems. The technology is also scalable, which makes the batteries ideal for commercial use and for electricity grid stabilisation.

Gelion has signed Memoranda of Understanding for 3 projects which will, if completed, provide 400MWh of offtake.

Gelion has also established a division focused on improving the performance of lithium-ion and lithium-sulfur batteries. Through its partners, Gelion anticipates having global, exclusive access to patented additives to improve the performance of lithium batteries for mobile energy storage such as for electric vehicles and aviation. These additives have been proven to greatly extend both energy density and cycle life.

Gelion UK Limited has been re-registered as a plc ahead of IPO.

DETAILS OF SECURITIES TO BE ADMITTED INCLUDING ANY RESTRICTIONS AS TO TRANSFER OF THE SECURITIES (i.e. where known, number and type of shares, nominal value and issue price to which it seeks admission and the number and type to be held as treasury shares):

106,463,839 ordinary shares of £0.001 each

No ordinary shares are or will be held in treasury.

The ordinary shares will be freely transferable and have no restrictions as to transfer placed on them.

CAPITAL TO BE RAISED ON ADMISSION (AND/OR SECONDARY OFFERING) AND ANTICIPATED MARKET CAPITALISATION ON ADMISSION:

Capital to be raised by placing: £9.78 million (£6.78 million primary and £3.00 million secondary, following a sell down by certain shareholders)

Capital to be raised by direct subscription: £9.26 million

Capital to be raised on Admission: £19.04 million (£16.04 million primary and £3.00 million secondary)

Please note that the company has also raised Capital of £6.00 million following a conversion of loan notes on Admission

Anticipated market capitalisation on admission £154.37 million.

38.92 per cent.

N/A

FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS (underlining the first name by which each is known or including any other name by which each is known):

Stephen ("Steve") Willliam Mahon - Non-Executive Chairman

Andrew Peter Grimes - Chief Executive Officer

Amit Gupta  - Chief Financial Officer

Michael Edward Davie - Independent Non-Executive Director

Joycelyn Cheryl Morton - Independent Non-Executive Director

Thomas Maschmeyer - Non-Executive Director

FULL NAMES AND HOLDINGS OF SIGNIFICANT SHAREHOLDERS EXPRESSED AS A PERCENTAGE OF THE ISSUED SHARE CAPITAL, BEFORE AND AFTER ADMISSION (underlining the first name by which each is known or including any other name by which each is known):

*Previously called Andyhow (Humphreys Family Super Fund)

**of which 0.22 per cent. relates to shares held by the Ashleworth Court Trust of which of Robin Chamberlayne is the beneficial holder

NAMES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH (H) OF THE AIM RULES:

None

(i)         30 June

(ii)        30 June 2021

(iii)       31 March 2022 (6 month unaudited results to 31 December 2021); 31 December 2022 (12 month audited results to 30 June 2022); 31 March 2023 (6 month unaudited results to 31 December 2022).

EXPECTED ADMISSION DATE:

30 November 2021

NAME AND ADDRESS OF NOMINATED ADVISER:

finnCap Ltd

1 Bartholomew Close

London

EC1A 7BL

NAME AND ADDRESS OF BROKER:

finnCap Ltd

1 Bartholomew Close

London

EC1A 7BL

OTHER THAN IN THE CASE OF A QUOTED APPLICANT, DETAILS OF WHERE (POSTAL OR INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BE AVAILABLE FROM, WITH A STATEMENT THAT THIS WILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS SECURITIES:

DATE OF NOTIFICATION:

25 November 2021

NEW/ UPDATE:

UPDATE